Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase Ib/IIa, Active-controlled, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Multiple Oral Doses of BTZ-043 Tablets in Subjects With Newly Diagnosed, Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis

NCT04044001 is registered in ClinicalTrials.gov with Michael Hoelscher as lead sponsor.

NCT NCT04044001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04044001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase Ib/IIa, Active-controlled, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Multiple Oral Doses of BTZ-043 Tablets in Subjects With Newly Diagnosed, Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis
Lead sponsor
Michael Hoelscher
Phase
Phase 1/2
Overall status
Completed
Start date
November 15, 2019
Completion date
May 31, 2022
Enrollment
78 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

other specified pulmonary tuberculosis, pulmonary tuberculoses